Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer. Celator’s proprietary technology platform, CombiPlex, enables the rational design and rapid evaluation of … Continue reading →

Intec Pharma Ltd. (NASDAQ: NTEC) is developing drugs based on its proprietary Accordion Pill platform technology. Accordion Pill is an oral drug delivery system designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing … Continue reading →

Amedica Corp. (NASDAQ: AMDA) develops Silicon Nitride orthopedic and spinal implants. It is the only company that has FDA approval to produce and distribute medical grade Silicon Nitride. Amedica’s line of Silicone Nitride Interbody Fusion implants are designed to participate … Continue reading →

Axsome Therapeutics, Inc. (Nasdaq: AXSM) is a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system, or CNS, disorders. By focusing on this therapeutic area, the company is addressing significant and growing … Continue reading →

Resverlogix Corp. (OTC: RVXCF) is an epigenetics company, creating small molecule therapeutics for BET inhibition. The company is currently developing apabetalone (RVX-208), a first-in-class, small molecule selective BET bromodomain inhibitor. It is the only selective BET bromodomain inhibitor in clinical … Continue reading →

Bionomics Ltd. (OTC: BNOEF) is a fully integrated, international drug discovery and development company creating new therapies that serve large unmet needs in cancer and central nervous system disorders such as depression, anxiety and Alzheimer’s. Bionomics has created proprietary technology … Continue reading →

CorMedix, Inc. (NYSE: CRMD) is a commercial-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. The company’s first commercial product in Europe is Neutrolin®, a catheter … Continue reading →

Enumeral Biomedical Holdings, Inc. (ENUM) is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. The company is building a pipeline focused on next-generation checkpoint modulators, with initial targets including … Continue reading →

Celsion Corp. (NASDAQ: CLSN), a fully-integrated oncology company, is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The company’s lead program is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently … Continue reading →

NanoViricides, Inc. (NYSE: NNVC) is a nano-biopharmaceutical company focused on discovering, developing, and marketing therapeutics for the treatment of viral infections. The company is developing anti-flu drug candidates at pre-clinical and advanced pre-clinical stage.  These candidates include two FluCide drugs … Continue reading →